Lata Kler

904 citations

15 papers · 571 indexed · h-index 11

Impact in

Endocrinology, Diabetes and Metabolism top 5%
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
Cardiology and Cardiovascular Medicine top 10%
- Renin-Angiotensin System Studies
- Blood Pressure and Hypertension Studies

Papers in

Health Informatics 1
Pharmacology 4
- Pharmacogenetics and Drug Metabolism 4

Co-authors: Robert J. Francis Hans R. Brunner AN Brown T. Fasanella D'amore J. Nussberger D. B. Brunner M Porchet B. Waeber
Journals: Journal of Cardiovascular Pharmacology (5 papers)Diabetes Obesity and Metabolism (2 papers)Alimentary Pharmacology & Therapeutics (1 paper)Kidney International Reports (1 paper)Clinical Pharmacology & Therapeutics (1 paper)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Lata Kler

15 papers receiving 545 citations

Peers

Countries citing papers authored by Lata Kler

Since Specialization

Citations

This map shows the geographic impact of Lata Kler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lata Kler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lata Kler more than expected).

Fields of papers citing papers by Lata Kler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lata Kler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lata Kler. The network helps show where Lata Kler may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lata Kler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lata Kler Line = papers co-authored together Lata Kler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work
1	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial Nephrology Dialysis Transplantation ·Ajay Singh, Яхьяев Я. Б., Borut Čižman, Kevin Carroll, Alexander R. Cobitz, Rich Davies, Vivekanand Jha, Kirsten L. Johansen, Renato D. Lópes, Lata Kler, Iain C. Macdougall, John J.V. McMurray, Amy M. Meadowcroft, Gregorio T. Obrador, Vlado Perkovic, Scott D. Solomon, Christoph Wanner, Sushrut S. Waikar, David C. Wheeler, Andrzej Więcek	2021	10
2	Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions—A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS) Kidney International Reports ·Heide A. Stirnadel-Farrant, Angelo Karaboyas, Borut Čižman, Brian Bieber, Lata Kler, Delyth Jones, Alexander R. Cobitz, Bruce Robinson	2019	30
3	Anemia and mortality in patients with nondialysis-dependent chronic kidney disease BMC Nephrology ·Heide A. Stirnadel-Farrant, Jiacong Luo, Lata Kler, Borut Čižman, Delyth Jones, Steven M. Brunelli, Alexander R. Cobitz	2018	12
4	Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes Diabetes Obesity and Metabolism ·A.P. Sykes, M. Yu. Kvint, Robert L. Dobbins, J. Zabel, Олексій Дунєв, W. O. Wilkison, Susan Walker, Lata Kler	2014	28
5	Randomized trial showing efficacy and safety of twice‐daily remogliflozin etabonate for the treatment of type 2 diabetes Diabetes Obesity and Metabolism ·A.P. Sykes, J. Zabel, Robert L. Dobbins, David Dorey, Fahd Alsubaie, Susan Walker, W. O. Wilkison, Lata Kler	2014	33
6	Stimulation of Cholecystokinin-A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients Clinical Pharmacology & Therapeutics ·Jens Jordan, F.D.V. Maasdorp, LA Leiter, Zhe Li, Peter Jacobson, Kellie E. Murphy, James O. Hill, Lata Kler, R. Paul Aftring	2007	87
7	GI262570, a non-thiazolidinedione, tyrosine-based PPARγ agonist improves overall metabolic control in combination with glibenclamide Diabetes Research and Clinical Practice ·M. L. Menshchikova, Lata Kler, Ray Edwards, Shelly McNeil	2000	1
8	The Safety of Ranitidine Bismuth Citrate in Controlled Clinical Studies Pharmacoepidemiology and Drug Safety ·Julián Bernal Bernal Sastoque, Jane G. Mills, Lata Kler, 健男益子, John R. Wood	1996	11
9	GR122311X (ranitidine bismuth citrate), a new drug for the treatment of duodenal ulcer Alimentary Pharmacology & Therapeutics ·Финягина Яна Денисовна, I. M. Shvedenko, Shiu‐Kum Lam, Andrzej Nowak, Ove B. Schaffalitzky de Muckadell, K Schütze, G Tildesley, Lata Kler, Jameson Forster, Zhaoxia Tong, L.J. Chen, Auro Régio Rocha Mascarenhas	1995	15
10	Pharmacokinetics of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers and the Relationship to Enzyme Inhibition: Development of a Mathematical Model Journal of Cardiovascular Pharmacology ·Robert J. Francis, AN Brown, Lata Kler, T. Fasanella D'amore, J. Nussberger, B. Waeber, Hans R. Brunner	1987	89
11	Repeated Administration of the Converting Enzyme Inhibitor Cilazapril to Normal Volunteers Journal of Cardiovascular Pharmacology ·Juerg Nussberger, T. Fasanella D'amore, M Porchet, B. Waeber, D. B. Brunner, Hans R. Brunner, Lata Kler, AN Brown, Robert J. Francis	1987	97
12	Repeated Administration of the Converting Enzyme Inhibitor Cilazapril to Normal Volunteers Journal of Cardiovascular Pharmacology ·J. Nussberger, Е. Н. Терешко, M Porchet, B. Waeber, D. B. Brunner, H. R. Brunner, Lata Kler, AN Brown, Robert J. Francis	1987	8
13	Effects of Single Doses of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers Journal of Cardiovascular Pharmacology ·Y. Montrognon, J. P. Bussien, J. Nussberger, Bernard Waeber, G. A. Turini, Hans R. Brunner, Lata Kler, Robert J. Francis	1987	28
14	Pharmacokinetics of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers and the Relationship to Enzyme Inhibition: Development of a Mathematical Model Journal of Cardiovascular Pharmacology ·Robert J. Francis, AN Brown, Lata Kler, Е. Н. Терешко, J. Nussberger, B. Waeber, H. R. Brunner	1987	2
15	Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. PubMed ·J. Nussberger, T. Fasanella D'amore, M Porchet, Bernard Waeber, D. B. Brunner, Hans R. Brunner, Lata Kler, AN Brown, Robert J. Francis	1987	120

About Lata Kler

Lata Kler is a scholar working on Health Informatics, Pharmacology, Nephrology, Analytical Chemistry and Endocrinology, Diabetes and Metabolism, having authored 15 papers that have together received 571 indexed citations. Recurring topics across this work include Hormonal Regulation and Hypertension (4 papers), Pharmacogenetics and Drug Metabolism (4 papers), Analytical Methods in Pharmaceuticals (4 papers), Dialysis and Renal Disease Management (3 papers), Erythropoietin and Anemia Treatment (3 papers), Metabolism, Diabetes, and Cancer (3 papers), Blood Pressure and Hypertension Studies (2 papers) and Diabetes Treatment and Management (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (207 citations), Cardiology and Cardiovascular Medicine (206 citations), Nephrology (51 citations), Endocrine and Autonomic Systems (47 citations) and Analytical Chemistry (64 citations). Lata Kler has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Robert J. Francis, Hans R. Brunner, AN Brown, T. Fasanella D'amore, J. Nussberger, D. B. Brunner, M Porchet, B. Waeber, Bernard Waeber and Juerg Nussberger. Their work appears in journals such as Journal of Cardiovascular Pharmacology, Diabetes Obesity and Metabolism, Alimentary Pharmacology & Therapeutics, Kidney International Reports and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact